Development of Nonalcoholic Fatty Liver Disease After Orthotopic Liver Transplantation for Cryptogenic Cirrhosis
Overview
General Surgery
Authors
Affiliations
Many subjects with cryptogenic cirrhosis have underlying nonalcoholic steatohepatitis (NASH). The natural history of NASH-related cryptogenic cirrhosis after orthotopic liver transplantation (OLT) is not well defined. A primarily retrospective study of patients with the clinical histological phenotype of NASH-related cirrhosis undergoing OLT was performed. Data were compared with 2 sets of age- and weight-matched controls with (1) primary biliary cirrhosis or primary sclerosing cholangitis or (2) alcoholic liver disease. After OLT, all patients were managed by a standard immunosuppressive protocol. Liver biopsies were performed at 6 and 12 months after OLT and at 1- to 2-year intervals thereafter, as well as when liver enzyme levels were elevated enough to warrant diagnostic biopsy. Twenty-seven subjects with cryptogenic cirrhosis and a clinical histological phenotype of NASH and 3 patients with a long-standing diagnosis of NASH before OLT were included. The 30-day perioperative mortality was 1 in 30 patients. During a median follow-up of 3.5 +/- 2.7 years, 2 additional patients died of sepsis. There was a time-dependent increase in the risk for allograft steatosis that approached 100% by 5 years compared with only an approximately 25% incidence of steatosis in the control groups (P <.009, log-rank test). On multivariate analysis, only the cumulative steroid dose correlated with time to development of allograft steatosis. Three patients developed histological progression from hepatic steatosis to steatohepatitis. Of these, 1 patient developed progressive fibrosis. Four patients experienced at least 1 episode of acute cellular rejection; however, no patient developed chronic rejection or graft failure. In conclusion, nonalcoholic fatty liver disease occurs frequently after OLT in patients with the phenotype of NASH-related cirrhosis. Despite the frequent histological recurrence of disease, clinical outcomes are similar to those of other groups of patients undergoing OLT.
Mac Curtain B, OBrien L, El Sherif O, Mc Cormack A, Carolan E, Ryan J Gastroenterol Hepatol Bed Bench. 2024; 17(1):17-27.
PMID: 38737926 PMC: 11080689. DOI: 10.22037/ghfbb.v17i1.2899.
Post-Liver Transplant Metabolic Syndrome.
Choudhury A, Singh S, Desmukh A, Sahoo B, Eslam M J Clin Exp Hepatol. 2024; 14(4):101368.
PMID: 38523736 PMC: 10960134. DOI: 10.1016/j.jceh.2024.101368.
Paklar N, Mijic M, Filipec-Kanizaj T Biomedicines. 2023; 11(11).
PMID: 38002096 PMC: 10669065. DOI: 10.3390/biomedicines11113096.
Adali G, Bilgic N, Kalaman A, Ozturk O, Ozdil K Hepatol Forum. 2023; 4(3):129-134.
PMID: 37822311 PMC: 10564255. DOI: 10.14744/hf.2023.2023.0032.
Bezinover D, Alhkouri N, Schumann R, Geyer N, Chinchilli V, Stine J Transplant Proc. 2023; 55(9):2134-2142.
PMID: 37752016 PMC: 10699163. DOI: 10.1016/j.transproceed.2023.08.020.